Apheresis
- 1 January 1995
- book chapter
- Published by Springer Nature
- Vol. 386, 175-184
- https://doi.org/10.1007/978-1-4613-0331-2_16
Abstract
Treatment of hemophilia patients with inhibitors is most effective if circulating levels of factor VIII (F.VIII) or factor EX (F.IX) can be obtained. This is possible not only in patients with low inhibitor concentration, but also in those with high inhibitor levels after temporary removal of the inhibitors by means of apheresis methods.This publication has 14 references indexed in Scilit:
- The Management of Hemophilia Patients With InhibitorsTransfusion Medicine Reviews, 1992
- Kinetic Aspects of the Removal of IgG and Inhibitors in Hemophiliacs Using Protein A Immunoadsorption1Vox Sanguinis, 1991
- Immunoadsorption for coagulation factor inhibitorsTransfusion, 1991
- Induction of Immune Tolerance in Patients with Hemophilia and Antibodies to Factor VIII by Combined Treatment with Intravenous IgG, Cyclophosphamide, and Factor VIIINew England Journal of Medicine, 1988
- Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies.Proceedings of the National Academy of Sciences, 1986
- Polymorphism of normal factor IX detected by mouse monoclonal antibodies.Proceedings of the National Academy of Sciences, 1985
- Serial plasmapheresis in a haemophiliac with antibodies to FVIII.Journal of Clinical Pathology, 1977
- Immunosuppressive Treatment in Haemophiliacs with Inhibitors to Factor VIII and Factor IXScandinavian Journal of Haematology, 1976
- Purification and characterization of human factor IXThrombosis Research, 1975